优化可成像的生物标记物

开发新药的工作正变得比以前更负挑战性。尽管用于研究和开发的花费在不断增长，但是目前上报申请法规批准的新药数量实际上正在减少。形成这种趋势的一个重要因素是用于高效评价药效和药物安全性的应用科学没有跟上药物研发的发展脚步。

Qptimising imaging biomarkers

Developing new drugs is more challenging than ever before, Despite growing expenditure on research and development, the number of new drugs being submitted for regulatory approval is actually decreasing. An important contributing factor to this trend is that the use of applied science to assess drug efficacy and safety more efficiently is not keeping up with drug discovery processes.